Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Mattson Financial Services LLC

Mattson Financial Services LLC boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 22.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,020 shares of the medical equipment provider's stock after purchasing an additional 3,350 shares during the quarter. Mattson Financial Services LLC's holdings in Zimmer Biomet were worth $1,945,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $25,000. Menard Financial Group LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at $30,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at $36,000. Kentucky Trust Co bought a new position in Zimmer Biomet during the 4th quarter worth $39,000. Finally, OFI Invest Asset Management bought a new position in Zimmer Biomet during the 4th quarter worth $40,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZBH shares. Robert W. Baird decreased their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $111.53.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Price Performance

NYSE ZBH traded down $1.22 during trading hours on Friday, hitting $92.12. The company had a trading volume of 3,505,131 shares, compared to its average volume of 1,805,125. The firm has a market capitalization of $18.23 billion, a price-to-earnings ratio of 20.70, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm has a 50 day simple moving average of $100.36 and a 200 day simple moving average of $104.92. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.92 and a 52 week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the firm posted $1.94 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.